Effect of structural analogs of butaclamol (a new antipsychotic drug) on striatal homovanillic acid and adenyl cyclase of olfactory tubercle in rats.
T A Pugsley, J Merker, W Lippman
Index: J. Physiol. Pharmacol. 54 , 510-515, (1976)
Full Text: HTML
Abstract
The 3-isopropyl (I), 3-cyclohexyl (II) and 3-phenyl (III) analogs of the new antipsychotic drug butaclamol, which contains a 3-tertiary butyl group, and their respective (+)-enantiomers, but not (-)-enantiomers, caused a dose related elevation of rat striatal homovanillic acid concentration, indicative of an increased dopamine (DA) turnover; droperidol also exhibited this activity. The order of activity of the (+)-enantiomers was (butaclamol) approximately II greater than I greater than III. A decrease in striatal DA was observed with (+)-I and (+)-III at the highest dose used, but not at one-half the dose. Each analog antagonized the DA-induced increase in adenyl cyclase (EC 4.6.1.1) activity of olfactory tubercle homogenates, the order of activity of the racemates (except for II) AND (+)-ENANTIOMERS BEING (BUTACLAMOL) APPROXIMATELY I greater than III greater than II. The (+)-enantiomers of butaclamol and analogs were two to four times more potent than their respective racemates, with (+)-butaclamol and (+)-I displaying activity generally equivalent to fluphenazine. The respective (-)-enantiomers were ineffective indicating a stereochemical specificity for DA-receptor blockade. Such analogs presented should be of value in elucidating dopaminergic mechansims.
Related Compounds
Related Articles:
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
2009-10-01
[Nat. Chem. Biol. 5 , 765-71, (2009)]
2000-02-18
[Neurosci. Lett. 280(2) , 135-8, (2000)]
2006-01-01
[BMC Neurosci. 7 , 28, (2006)]
2012-08-01
[Genetika 48(8) , 999-1002, (2012)]
2008-06-01
[J. Neurophysiol. 99(6) , 2844-63, (2008)]